기자가 쓴 기사 더보기

[편집자 주 - 너무 어린 아이들이 강력한 향정신성 의약품에 쉽게 노출되어 있다는 기사입니다]
At 18 months, Kyle Warren started taking a daily antipsychotic drug on the orders of a pediatrician to quell the boy's severe tempter tantrums.
Thus began a troubled toddler's journey from one doctor to another, from one diagnosis to another, involving even more drugs. Autism, bipolar disorder, hyperactivity, insomnia, oppositional defiant disorder. The boy's daily pill regimen multiplied: the antipsychotic Risperdal [리스페달], the antidepressant Prozac [프로작], two sleeping medicines and one for attention-deficit disorder. All by the time he was 3.
He was sedated, drooling and overweight from the side effects of the antipsychotic medicine. Although his mother, Brandy Warren, had been at her "wit's end" when she resorted to the drug treatment, she began to worry about Kyle's altered personality.
"All I had was a medicated little boy," Ms. Warren said. "I didn't have my son. It's like, you'd look into his eyes, and you would just see just blankness."
Today, Kyle, 6, is in his forth week of first grade, scoring high marks on his first tests. He is rambunctious and much thinner. Weaned off the drugs through a program affiliated with Tulane University in New Orleans [U.S.A.] that is aimed at helping low-income families whose children have mental health problems, Kyle now laughs easily and teases his family.
Ms. Warren and Kyle's new doctors point to his remarkable progress - and a more common diagnosis for children of attention-deficit hyperactivity disorder - as proof that he should have never been prescribed such powerful drugs in the first place.
| 인기기사 | 더보기 + |
| 1 | [바이오유럽-포토] 바이오 유럽 2026 “더는 밀리지 않겠다” 반격 나선 유럽 |
| 2 | [바이오유럽-인터뷰] 넥스아이 “NXI-201 기술이전 협상 상당히 진전”…27년 빅딜 정조준上 |
| 3 | "AI가 제안하고 연구자가 검증"…한미·대웅, 신약개발 혁신 가속 |
| 4 | “글로벌 빅파마, MIDD 데이터 내놔라”…신약 기술수출 실사 기준 높아졌다 |
| 5 | 메지온,차세대 파이프라인 ‘ADPKD’ 내년 1월 미국 FDA ‘Pre-IND’ |
| 6 | [바이오유럽] 압타바이오 이수진 대표 “임상 PoC로 기업가치 점프…빅파마 경쟁입찰 추진” |
| 7 | 동물실험 시대 저물고 'NAMs' 뜬다… 국내 제약바이오 산업 생존 전략은? |
| 8 | [바이오유럽-인터뷰] 넥스아이 "ADC로 기술이전 릴레이…빅파마 주목 신규 타깃 6개 확보"下 |
| 9 | 슈도에페드린 사태에 일반약 관리 강화…약사회, 법 개정 추진 |
| 10 | 약사회 "한약사 피해 공감하지만…교차고용 해결이 협의체 선결 조건" |
| 인터뷰 | 더보기 + |
| PEOPLE | 더보기 + |
| 컬쳐/클래시그널 | 더보기 + |

[편집자 주 - 너무 어린 아이들이 강력한 향정신성 의약품에 쉽게 노출되어 있다는 기사입니다]
At 18 months, Kyle Warren started taking a daily antipsychotic drug on the orders of a pediatrician to quell the boy's severe tempter tantrums.
Thus began a troubled toddler's journey from one doctor to another, from one diagnosis to another, involving even more drugs. Autism, bipolar disorder, hyperactivity, insomnia, oppositional defiant disorder. The boy's daily pill regimen multiplied: the antipsychotic Risperdal [리스페달], the antidepressant Prozac [프로작], two sleeping medicines and one for attention-deficit disorder. All by the time he was 3.
He was sedated, drooling and overweight from the side effects of the antipsychotic medicine. Although his mother, Brandy Warren, had been at her "wit's end" when she resorted to the drug treatment, she began to worry about Kyle's altered personality.
"All I had was a medicated little boy," Ms. Warren said. "I didn't have my son. It's like, you'd look into his eyes, and you would just see just blankness."
Today, Kyle, 6, is in his forth week of first grade, scoring high marks on his first tests. He is rambunctious and much thinner. Weaned off the drugs through a program affiliated with Tulane University in New Orleans [U.S.A.] that is aimed at helping low-income families whose children have mental health problems, Kyle now laughs easily and teases his family.
Ms. Warren and Kyle's new doctors point to his remarkable progress - and a more common diagnosis for children of attention-deficit hyperactivity disorder - as proof that he should have never been prescribed such powerful drugs in the first place.